Evidence map›Paper›PMID 35241561›Full record

ArticleIn vivo (Athens, Greece)

Clinical Influence of the Lymph Node Ratio on Lymph Node Metastasis-positive Gastric Cancer Patients Who Receive Curative Treatment.

Toru Aoyama, Kesikeu Komori, Ayako Tamagawa, Masato Nakazano, Kentaro Hara, Itaru Hashimoto, Hiroshi Tamagawa, Kenki Segami, Yukio Maezawa, Kazuki Kano and 3 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Low Expression of miR-491-3p Is Correlated with Lymph Node Metastasis in Gastric Cancer.Evidence-based complementary and alternative medicine : eCAM · 2022
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Toru Aoyama *Department of Surgery, Yokohama City University, Yokohama, Japan; t-aoyama@lilac.plala.or.jp.
Kesikeu Komori *Department of Surgery, Yokohama City University, Yokohama, Japan.
Ayako TamagawaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Masato NakazanoDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Kentaro HaraDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Itaru HashimotoDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Hiroshi TamagawaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Kenki SegamiDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Yukio MaezawaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Kazuki KanoDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Takashi OshimaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Norio YukawaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Yasushi RinoDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Yokohama City University · JPKanagawa Cancer CenterKanagawa Prefectural Hospital Organization · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThe present study investigated the clinical impact of the lymph node ratio (LNR) on overall survival (OS) and recurrence-free survival (RFS) in cancer patients with lymph node metastasis who received curative treatment. PATIENTS AND

methodsEighty-six patients who received curative surgery for gastric cancer between 2000 and 2015, and in whom lymph node metastasis was pathologically confirmed, were included in this study. The LNR was defined as the ratio of the number of metastatic lymph nodes to the total number of harvested lymph nodes.

resultsA lymph node ratio of 0.23 was considered the optimal cutoff point for classification according to OS. Statistically significant differences were observed in the 3- and 5-year OS rates and 3- and 5-year RFS rates. The 3-year and 5-year OS rates in the LNR <0.23 group were 57.6% and 57.6%, respectively, whereas those in the LNR ≥0.23 group were 33.0% and 0% (p<0.001). The 3-year and 5-year RFS rates in the LNR <0.23 group were 45.9% and 43.6%, respectively, whereas those in the LNR >0.23 group were 25.2% and 0% (p=0.002). Regarding the site of first relapse, the incidence rates of peritoneal and lymph node metastasis in the LNR >0.23 group were significantly different in comparison to the LNR <0.23 group.

conclusionA high LNR was associated with significantly worse OS and RFS in patients who received curative treatment for gastric cancer. The lymph node metastasis status should be utilized in the development of treatment strategies for gastric cancer.

Indexed as

Lymph Node RatioStomach NeoplasmsHumansLymphatic MetastasisLymph Node ExcisionLymph NodesNeoplasm StagingPrognosisRetrospective StudiesGastric cancerlymph node metastasis-positivelymph node ratio

Identifiers

PMID35241561
PMCPMC8931879
OpenAlexW4214929946

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.